Therefore, VE-cadherin in cancer cells keeps its cytoskeleton binding capacity (actin-binding) but does not seem to require the interaction with β-catenin for SRC or FAK activation, as it does in endothelial cells [16]. The gene discussed is CDH5; the disease is cancer.